Ticker Symbol: OTLK
Outlook Therapeutics Inc
$2.00 - 20-11-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001649989
Company Profile
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 4260 U.S. Route 1
Website: outlooktherapeutics.com
CEO: Lawrence Kenyon
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.23
Change:
$0.01
(
6.26%)
Days Range: $0.21 - $0.23
Beta: 0.64
52wk. High: $2.02
52wk. Low: $0.20
Ytd. Change -73.03%
50 Day Moving Average: $0.25
200 Day Moving Average: $1.13
Shares Outstanding: 260245017
Valuation
Market Cap: 6.2B
PE Ratio: -0.24
EPS (TTM): -0.9995
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A